Introduction
The venture capital market has been especially unforgiving toward first-time fund managers, yet Sahir Raoof has defied the trend. The former SignalFire principal and healthcare industry veteran has closed a $27.5 million debut fund through his firm, Proximal Ventures. The capital will support early-stage companies applying artificial intelligence to the services and infrastructure behind pharmaceutical research and drug development.
What Happened
Proximal Ventures is focused on the layer of drug development that pharmaceutical companies have traditionally outsourced to specialized service providers. This includes tasks such as synthesizing molecular compounds, scaling up manufacturing, and analyzing data from clinical trials. Raoof argues that AI can automate significant portions of this work, allowing startups to offer comparable services faster and at lower cost while tapping into billions of dollars in existing pharmaceutical spending.
The fund intends to deploy capital ranging from $500,000 to $1.5 million per investment, focusing on pre-seed and seed-stage companies. It has already placed bets on seven startups. One of them is ChronicleBio, co-founded by former OpenAI executive Fidji Simo, which leverages artificial intelligence to examine biological and medical data, aiming to better understand chronic diseases and uncover potential treatment options.
Why This Matters
Raoof's background gives him a distinctive vantage point. His career includes a two-year stint as a principal at SignalFire, business development leadership at clinical trial recruitment company Iterative Health, and partnership oversight at Flatiron Health, an oncology data firm acquired by Roche for $1.9 billion. He notes that life sciences companies often struggle to build their first commercial relationships, a challenge he says his sales experience and industry connections are positioned to address.
The fundraising itself signals confidence from a range of established backers. Limited partners include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors Nan Li and Zavain Dar of Dimension Capital. Amy Abernethy, a former FDA official and Flatiron Health alum who co-founded Highlander Health, also invested. She cited Raoof's ability to identify industry bottlenecks and build lasting relationships as reasons for her support.
Key Takeaways
- Proximal Ventures raised $27.5 million for its first fund despite a difficult market for first-time managers.
- The firm targets pre-seed and seed startups using AI to improve pharmaceutical services and drug development infrastructure.
- Initial investments include ChronicleBio, co-founded by former OpenAI executive Fidji Simo.
- Backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and Dimension Capital co-founders Nan Li and Zavain Dar.
- Amy Abernethy, former FDA principal deputy commissioner and Flatiron Health veteran, is also a limited partner.
Conclusion
For founders building AI tools for the life sciences, Proximal Ventures represents a new source of early-stage capital and industry expertise. By combining technical investment with deep healthcare relationships, Raoof aims to help portfolio companies overcome the commercial hurdles that often slow down life sciences startups. Whether the fund can deliver outsized returns remains to be seen, but its launch shows that targeted, experience-backed managers can still attract capital in a selective fundraising climate.

Discussion
Join the conversation
Thoughtful reactions, questions, and follow-up ideas help shape the next story.